Botulinum toxin a in the treatment of blepharospasm: A 10-year experience

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 2, 2005, Pages 221-224

  Silveira Moriyama, Laura ^a,b   Goncalves, Lilian R ^a   Chien, Hsin Fen ^a   Barbosa, Egberto R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HC FMUSP ^*  (Brazil)

Author keywords

Blepharospasm; Botulinum toxin; Dystonia

Indexed keywords

BOTULINUM TOXIN A;

ADULT; APRAXIA; ARTICLE; BLEPHAROSPASM; CONTROLLED STUDY; DYSTONIA; HUMAN; INJECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; PTOSIS;

EID: 20644455350     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2005000200006     Document Type: Article

References (20)

1. Moore P. General and clinical aspects of treatment with botulinum toxin. In Handbook of botulirvum toxin treatment. Oxford: Blackwell Science, 1995:28-54.
2. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 2004;19(Supp 8):S2-S6.
3. Misra VPThe changed image of botulinum toxin. Br Med J 2002;325:1188.
4. Workshop: "Treinamento para aplicacao de toxina botulinica em distonias e espasmo hemifacial", ministrado pelo Dr Earl Consky no Departamento de Neurologia da Escola Paulista de Medicina, São Paulo: 1991.
5. Barbosa ER, Silva HCA, Haddad MS, Bittar MS. Blefaroespasmo: tratamento com toxina Botulinica. Rev Hosp Clin Fac Med S Paulo 1996;51:220-223.
6. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-1718.
7. Dressier D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;19(Supp 8):S92-S100.
8. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
9. Tolosa E, Marti MJ. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects. Adv Neurol 1988;49:73-84.
10. Jankovic JJ, Tolosa E. Parkinson's disease and movement disorders, Fourth Edition, Philadelphia: Lippincott Williams & Wilkins, 2002:331-364.
11. Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002;59:418-420.
12. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53:2102-2107.
13. Schnider P, Moraku E, Kittler H, et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow up in 61 patients. Br J Dermatology 2001;145:289-293.
14. D'Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis 2002;34:105-110.
15. Hsiung G-Y, Das SK, Ranawaya R, Lafontaine AL, Sucherovvsky O. Longterm efficacy of botulinum toxin A in the treatment of various disorders over a 10 year-period. Mov Disord. 2002;17:1288-1293.
16. Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992;12:121-127.
17. Naumann M, Moore AP. Long-term safety of botulinum toxin type A. Mov Disord. 2003;18:1080-1081.
18. Dressier D. Botulinum toxin therapy. New York:Thieme, 2000:39-93.
19. Krack P, Marion MH. "Apraxia of lid opening" a focal eyelid dystonia: clinical study of 32 patients. Mov Disord. 1994;9:610-615.
20. Dressier D. Complete secondary botulinum toxin therapy failure inblepharospasm. J Neurol 2000;247:809-810.